Premium
5‐fluorouracil and low‐dose recombinant interferon‐α‐2a in patients with hormone‐refractory adenocarcinoma of the prostate
Author(s) -
Shinohara Nobuo,
Demura Takayoshi,
Matsumura Kinya,
Toyoda Kenichi,
Kashiwagi Akira,
Nagamori Satoshi,
Ohmuro Hiroshi,
Ohzono Seiichirou,
Koyanagi Tomohiko
Publication year - 1998
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19980401)35:1<56::aid-pros8>3.0.co;2-f
Subject(s) - medicine , prostate cancer , refractory (planetary science) , chemotherapy , regimen , gastroenterology , fluorouracil , toxicity , intramuscular injection , prostate , urology , bolus (digestion) , surgery , oncology , cancer , physics , astrobiology
Abstract BACKGROUND The effectiveness of a chemotherapy regimen including 5‐fluorouracil (5‐FU) and recombinant interferon‐α‐2a (rIFN‐α‐2a) was evaluated in hormone‐refractory prostate cancer patients. METHODS Patients received a continuous intravenous infusion of 5‐FU at 600 mg/m 2 /day for 5 days (D1–D5), followed by a bolus injection of 5‐FU on D15 and D22. Patients received intramuscular injection of rIFN‐α‐2a at 3 million IU on D1, D3, D5, D15, and D22. This schedule was repeated every 4 weeks. RESULTS Between 1993 and 1995, 23 patients with hormone refractory prostate cancer were enrolled in this study. Two of five patients with nodal disease exhibited partial responses according to the NPCP criteria. Fourteen of 17 patients with bone disease showed stable disease. Of 21 patients assessible for response, 9 patients had a decrease in the PSA level greater than 50% of baseline. Bone pain disappeared partially or completely in 8 of 14 patients with this symptom at entry. The median overall survival was 18 months. The associate toxicity was well tolerable. CONCLUSIONS Combination chemotherapy of 5‐FU and low dose rIFN‐α‐2a in patients with hormone‐refractory prostate cancer proved feasible, and with acceptable toxicity. Prostate 35:56–62, 1998. © 1998 Wiley‐Liss, Inc.